Hepatocellular carcinoma surveillance—Utilization, barriers and the impact of changing aetiology
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide.
Surveillance for HCC is critical for early detection and treatment, but fewer than one-quarter …
Surveillance for HCC is critical for early detection and treatment, but fewer than one-quarter …
[HTML][HTML] Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic …
DJH Tan, CH Ng, SY Lin, XH Pan, P Tay… - The Lancet …, 2022 - thelancet.com
Background The clinical presentation and outcomes of non-alcoholic fatty liver disease
(NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular …
(NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular …
Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer
Liver cancer epidemiology is changing due to increasing alcohol consumption, rising
prevalence of obesity, and advances in hepatitis B virus (HBV) and hepatitis C virus (HCV) …
prevalence of obesity, and advances in hepatitis B virus (HBV) and hepatitis C virus (HCV) …
Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH
Global burden of liver cancer in males and females: Changing... : Hepatology Global burden of
liver cancer in males and females: Changing etiological basis and the growing contribution of …
liver cancer in males and females: Changing etiological basis and the growing contribution of …
Nonalcoholic fatty liver disease and hepatocellular carcinoma: Insights in epidemiology, pathogenesis, imaging, prevention and therapy
SA Polyzos, L Chrysavgis, ID Vachliotis… - Seminars in cancer …, 2023 - Elsevier
Hepatocellular carcinoma (HCC) is estimated to be the third leading cause of cancer-related
mortality and is characterized by low survival rates. Nonalcoholic fatty liver disease (NAFLD) …
mortality and is characterized by low survival rates. Nonalcoholic fatty liver disease (NAFLD) …
Multicenter validation of abbreviated MRI for detecting early-stage hepatocellular carcinoma
Background Abbreviated MRI is a proposed paradigm shift for hepatocellular carcinoma
(HCC) surveillance, but data on its performance are lacking for histopathologically confirmed …
(HCC) surveillance, but data on its performance are lacking for histopathologically confirmed …
[HTML][HTML] Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
Nonalcoholic fatty liver disease (NAFLD) affects about a third of the world's adult population
and is a major public health concern. NAFLD is defined by the presence of hepatic steatosis …
and is a major public health concern. NAFLD is defined by the presence of hepatic steatosis …
Shared mechanisms between cardiovascular disease and NAFLD
The burden of nonalcoholic fatty liver disease (NAFLD) is rising globally. Cardiovascular
disease is the leading cause of death in patients with NAFLD. Nearly half of individuals with …
disease is the leading cause of death in patients with NAFLD. Nearly half of individuals with …
the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD
M Amangurbanova, DQ Huang… - Alimentary …, 2023 - Wiley Online Library
Background Non‐alcoholic fatty liver disease (NAFLD) occurs in around a quarter of the
global population and is one of the leading causes of chronic liver disease. The phenotypic …
global population and is one of the leading causes of chronic liver disease. The phenotypic …
Clinical utility of combined MRI-PDFF and ALT response in predicting histologic response in nonalcoholic fatty liver disease
DQ Huang, SR Sharpton… - Clinical …, 2023 - cghjournal.org
Methods This longitudinal prospective study included 108 consecutive well-phenotyped
patients (61% women) with biopsy-proven NAFLD who underwent detailed standardized …
patients (61% women) with biopsy-proven NAFLD who underwent detailed standardized …